jaykza
Sep 23, 9:38 PM
$CYRX Given the Anthropic enzyme discovery news, pretty simple and compelling thesis for Cryoport growth prospects. Once
$CYRX becomes a cold storage logistics provider for a treatment in Phase 1/2/3, there are massive switching costs. As they continue to add treatments as a leader in CGT treatment logistics and these will graduate up to commercially approved at some % rate. Over time, we will see S-curves stacking as these treatments ramp. The image is just to show the impact of these treatments graduating to commercial approval over time.
2 replies